Congratulations to debra of America on a successful and impactful #debracareconference! The Aegle Therapeutics team was a proud sponsor of the event and is thankful for the opportunity to meet with so many in the EB community. #EpidermolysisBullosa
Aegle Therapeutics
Biotechnology Research
Woburn, MA 889 followers
Developing extracellular vesicle (EV) therapies to address rare and serious diseases and disorders
About us
Aegle Therapeutics Corp. is a clinical-stage biotechnology company developing novel extracellular vesicle (“EV”) therapies to address rare and serious diseases and disorders with significant unmet medical needs. Aegle’s proprietary platform technology safely isolates native extracellular vesicles (“EVs”) from stem cells. These EVs carry complex assemblies of biologic molecules such as proteins and nucleic acids that can induce a wide variety of effects in recipient cells, including the promotion of regenerative healing, while reducing inflammation and modulating the immune system. Aegle’s EV therapy has the potential to treat a broad range of indications in multiple therapeutic areas, including dermatology, immunology-based diseases, protein deficient disorders and others. For more information about Aegle Therapeutics, please visit www.aegletherapeutics.com.
- Website
-
https://aegletherapeutics.com/
External link for Aegle Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Woburn, MA
- Type
- Privately Held
Locations
-
Primary
Woburn, MA, US
Employees at Aegle Therapeutics
Updates
-
The Aegle team is thrilled to join debra of America next week in Atlanta as a sponsor of the #debraCareConference. We're looking forward to meeting with the EB community and presenting on Tuesday afternoon. #EpidermolysisBullosa Aegle Therapeutics is enrolling its 1/2a clinical trial of AGLE-102™ in individuals living with Recessive Dystrophic Epidermolysis Bullosa. AGLE-102 is an innovative topical treatment that uses extracellular vesicles from stem cells to promote wound healing and skin regeneration. Learn more: https://lnkd.in/etyZHU58
-
Thank you debra of America for hosting us last week for a webinar. The recording of "Unlocking Potential: Aegle's New Clinical Trial for RDEB Wounds" is now available online: https://lnkd.in/g7WmiNXk
Missed last week’s webinar with Aegle Therapeutics or want to watch it again? Great news —the recording is now available! Discover how Aegle's innovative topical treatment, AGLE-102™, uses extracellular vesicles from stem cells to promote wound healing and skin regeneration. Learn about the latest RDEB clinical trial and find out how to get involved. 🔗Watch now at https://lnkd.in/g7WmiNXk
-
Now Enrolling! Aegle's Phase 1/2a clinical trial of AGLE-102 in individuals living with Recessive Dystrophic Epidermolysis Bullosa (RDEB) is now open for enrollment. To learn more about the Aegle DEB Clinical Study, please see our Informational Brochure or visit ClinicalTrials.gov. Informational Brochure: https://lnkd.in/eUJjyVGW
-
Aegle Therapeutics CEO Shelley A. Hartman will co-chair the Exosome Characterization & Analytical Development Summit in Boston this week. We hope to see you there! 50+ EV Analytical Development leaders will converge to delve into the cutting-edge realm of exosome characterization and analytical approaches - from assay to data requirements. https://ter.li/iog378
Exosome Characterization & Analytical Development Summit - Home
exosome-analytical-development.com
-
We’re thrilled to announce positive data for the first patient in a Phase 1/2a clinical trial dosed with AGLE-102, a novel extracellular vesicle therapy. Learn more: https://lnkd.in/e-du-FBS
Aegle Therapeutics Corp. Announces Positive Data for the First Patient in a Phase 1/2a Clinical Trial Dosed With AGLE-102™, a Novel Extracellular Vesicle Therapy
prnewswire.com
-
Aegle Therapeutics CEO Shelley A. Hartman is kicking off the New Year with a presentation at #BiotechShowcase on Monday, January 8th at 10:15am (Franciscan A-Ballroom Level). We look forward to connecting with many of you at the conference!
-
Aegle Therapeutics CEO Shelley A. Hartman joined BioWorld and other biopharma executives to discuss 2023 challenges and opportunities for the year ahead. Check out the insightful podcast! https://lnkd.in/eg48P8yz
-
Aegle Therapeutics is excited to present at #BiotechShowcase on January 8th! We hope to see you in San Francisco for the healthcare conference.
-
Today is #GivingTuesday, a global day of generosity. Aegle Therapeutics is a proud supporter of debra of America and its mission to improve the quality of life for all people living with #EpidermolysisBullosa. Thank you debra of America for spotlighting Willistine Lenon, VP of Clinical Operations at Aegle Therapeutics and her passion for #EB advocacy.
As we celebrate the spirit of generosity this #GivingTuesday on November 28, debra of America is thrilled to spotlight some of our outstanding supporters! 🦋✨ Meet Willistine Lenon, VP of Clinical Operations at Aegle Therapeutics. Willistine is a passionate advocate for the Epidermolysis Bullosa (EB) Community, contributing both through her work and personal life. ➡️ Read Willistine’s story at https://lnkd.in/dnEnwRtZ